PA-BOOMI
8.5.2024 18:01:35 CEST | Business Wire | Press release
Boomi™, the intelligent integration and automation leader, today announced the acquisitions of APIIDA’s federated API management business and API management assets from Cloud Software Group, allowing enterprises to rapidly and securely deliver business value through API products in one end-to-end platform. Both these acquisitions accelerate Boomi’s roadmap for providing solutions to the most pressing API management challenges that companies face today.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508324428/en/
Boomi Doubles Down on API Management with Key Acquisitions (Graphic: Business Wire)
“APIs are the backbone of modern software and application development, and have become a cornerstone of modern architectures that enable businesses to stay agile and compete effectively,” said Steve Lucas, CEO at Boomi. “However, cloud adoption and the explosive growth of APIs have disrupted traditional IT infrastructures. With these acquisitions, we’re putting an end to operational overhead and API sprawl by offering a robust, enterprise-grade and federated API management solution, giving customers the ability to quickly provision, discover, secure, and infinitely scale in one end-to-end enterprise platform.”
APIIDA Federated API Management
As the market-leading solution for federated API management, APIIDA’s API Control Plane expands Boomi’s portfolio by offering the ability for enterprises to discover, govern, and provision APIs from one central place, including APIs managed through gateways from various vendors. This allows a vendor-agnostic, federated administration of the entire API lifecycle, and can be adapted to the requirements of any organization, enabling a consistent consumer experience and governance across all APIs.
By offering federated API management, Boomi enables enterprises to:
- Reduce complexity and cost by unifying access to all their APIs across cloud-based and on-premises API gateways from multiple vendors
- Drive innovation with a single destination for application developers, simplifying API consumption and accelerating time-to-market by giving developers a dynamic catalog where APIs can be discovered and reused
- Enhance provider security and governance with total visibility and control over all their APIs
“Companies that rely on a manual, fragmented approach to registering, managing, and publishing APIs across distributed platforms risk having those APIs be undiscovered, overlooked, and hence unadopted by users and applications that could benefit from them,” said Jaime Ryan, Vice President of Product, API Management at Boomi. “To successfully enable digital transformation, businesses need a proven, reliable way to connect applications and other data sources. With federated API management, customers will be able to reduce time to value with a single control plane for wherever APIs are deployed, providing better discovery, governance, and collaboration while making existing APIs more visible, subscribable, and consumable.”
API Management Assets From Cloud Software Group
Further accelerating the company’s API management roadmap, Boomi has also acquired assets from Cloud Software Group, providing Boomi customers enterprise-grade scalability and security. These assets, developed by a team that helped invent the API economy and used by some of the world’s largest organizations, will enable the Boomi Enterprise Platform to support even the most demanding API management performance and security requirements in markets such as travel, retail, tech, finance, and healthcare.
Additional Resources
- Read more about Boomi’s latest acquisitions
- Follow Boomi on X, LinkedIn, Facebook, and YouTube
About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.
© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240508324428/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom